Babafemi Taiwo
A5015872083- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Mycobacterium research and diagnosis
- Tuberculosis Research and Epidemiology
- Adolescent Sexual and Reproductive Health
- HIV, Drug Use, Sexual Risk
- Cytomegalovirus and herpesvirus research
- Pneumocystis jirovecii pneumonia detection and treatment
- SARS-CoV-2 detection and testing
- Hepatitis C virus research
- Long-Term Effects of COVID-19
- Infectious Diseases and Mycology
- Mobile Health and mHealth Applications
- Lipoproteins and Cardiovascular Health
- Cervical Cancer and HPV Research
- Genital Health and Disease
- COVID-19 and Mental Health
- Bone fractures and treatments
- Nutrition and Health in Aging
- Orthopedic Surgery and Rehabilitation
- Frailty in Older Adults
Northwestern University
2016-2025
Vanderbilt University
2025
Johnson & Johnson (Sweden)
2024
Center for Global Health
2013-2023
Royal Sussex County Hospital
2023
Association Clinique et Thérapeutique Infantile du Val de Marne
2022
Baylor College of Medicine
2020
Parkland Health & Hospital System
2020
Baylor Scott & White Health
2020
South Texas Veterans Health Care System
2020
BackgroundSevere coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.MethodsWe conducted double-blind, randomized, placebo-controlled trial evaluating baricitinib in hospitalized adults Covid-19. All the patients received (≤10 days) and either (≤14 or placebo (control). primary outcome was time to recovery. key secondary clinical status at day 15.ResultsA...
Effective treatments for patients with severe COVID-19 are needed.To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in hospitalized COVID-19.This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals Europe and United States. A total 454 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), systemic hyperinflammation defined by increased blood concentrations C-reactive protein or ferritin were enrolled between...
Although symptom and viral rebound have been reported after nirmatrelvir-ritonavir treatment, the trajectories of symptoms load during natural course COVID-19 not well described.To characterize in untreated outpatients with mild to moderate COVID-19.Retrospective analysis participants a randomized, placebo-controlled trial. (ClinicalTrials.gov: NCT04518410).Multicenter trial.563 receiving placebo ACTIV-2/A5401 (Adaptive Platform Treatment Trial for Outpatients With COVID-19) platform...
To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients.
We sought to describe virologic and clinical retention outcomes among a group of HIV-infected adolescents young adults (AYA) newly established in an adult HIV clinic compared with matched adults. AYA demonstrated lower rates HIV-1 suppression higher viral rebound loss follow-up African American had the lowest highest rebound. Adult providers should consider AYA, particularly potentially be at high risk for poor care.
Population sequencing was performed for persons identified with persistent low-level viremia in 2 clinical trials. Persistent (defined as plasma HIV-1 RNA level >50 and <1000 copies/mL at least determinations over a 24-week period, after 24 weeks of antiretroviral therapy) observed 65 (5.6%) 1158 patients risk. New resistance mutations were detected during 37% the 54 evaluable cases. The most common M184I/V (14 cases), K103N (9), M230L (3). Detection new associated higher levels viremia.
ABSTRACT A goal of HIV therapy is to sustain suppression the plasma viral load below detection limits clinical assays. However, widely followed treatment guidelines diverge in their interpretation and recommended management persistent viremia low magnitude, reflecting limited evidence base for this common finding. Here, we review incidence, risk factors, potential consequences low-level (LLV; defined as a level 50 500 copies/ml) very-low-level (VLLV; <50 copies/ml detected by assays that...
Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. A5353 is a phase 2, single-arm, pilot study of once-daily (50 mg) lamivudine (300 in treatment-naive participants HIV-1 RNA ≥1000 and <500000 copies/mL. Exclusion criteria included active hepatitis B or major protease, reverse transcriptase, integrase resistance. The primary efficacy measure was the proportion <50 copies/mL (FDA [US Food Drug Administration] Snapshot) at...
Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal antibodies with an extended half-life. Objective: To assess the safety efficacy amubarvimab plus romlusevimab. Design: Randomized, placebo-controlled, phase 2 3 platform trial. (ClinicalTrials.gov: NCT04518410) Setting: Nonhospitalized patients COVID-19 in United States, Brazil, South Africa, Mexico, Argentina, Philippines. Patients:...
Introduction: The clinical and public health implications of the convergence human immunodeficiency virus (HIV) epidemic chronic viral hepatitis in sub-Saharan Africa are poorly understood. This study was designed to determine seroprevalence B (HBV) C (HCV), impact co-infection on baseline serum alanine transaminase (ALT), CD4+ T lymphocyte (CD4) count, plasma HIV-RNA (viral load) a cohort HIV-infected Nigerians. Methods: A retrospective conducted, eligible treatment-naive patients who...
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There no emergence drug resistance in the participant who experienced virologic failure while receiving lamivudine. NCT02263326
Both frailty and falls occur at earlier-than-expected ages among HIV-infected individuals, but the contribution of frailty-to-fall risk in this population is not well understood. We examined association participants enrolled AIDS Clinical Trials Group (ACTG) A5322.A prospective, multicenter cohort study men women aged least 40 years.Frailty assessment included a 4-m walk, grip strength, self-reported weight loss, exhaustion, low physical activity. Multinomial logistic regression assessed...
The impact of antiretroviral therapy (ART) on frailty among human immunodeficiency virus (HIV)-infected adults has not been well described. HIV-infected participants aged ≥40 years with initial ART receipt through a randomized, controlled AIDS Clinical Trials Group trial completed assessment. Ordinal logistic regression models examined factors associated frailty. Of 1016 participants, 6% were frail, and 38% prefrail. Frailty was lower education, older age, Medicare/Medicaid, efavirenz,...
Background. Rifaximin, a nonabsorbable antibiotic that decreases lipopolysaccharide (LPS) in cirrhotics, may decrease the elevated levels of microbial translocation, T-cell activation and inflammation human immunodeficiency virus (HIV)-positive immune nonresponders to antiretroviral therapy (ART). Methods. HIV-positive adults receiving ART for ≥96 weeks with undetectable viremia ≥48 CD4+ counts <350 cells/mm3 were randomized 2:1 rifaximin versus no study treatment 4 weeks. activation, LPS,...
The purpose of this study was to compare the risks incident heart failure (HF) among a variety chronic inflammatory diseases (CIDs) and determine whether varied by severity inflammation within each CID. Individuals with CIDs are at elevated risk for cardiovascular diseases, but data limited regarding HF. An electronic health records database from large urban medical system examined, comparing individuals frequency-matched controls without CIDs, all whom were receiving regular outpatient...
Disparities in SARS-CoV-2 genomic surveillance have limited our understanding of the viral population dynamics and may delay identification globally important variants. Despite being most populated country Africa, Nigeria has remained critically under sampled. Here, we report sequences from 378 isolates collected Oyo State, between July 2020 August 2021. In early 2021, belonged to Alpha "variant concern" (VOC) or Eta lineage. outcompeted across West persisting region even after expansion an...
<h3>Importance</h3> Nigeria has the fourth-largest HIV epidemic globally, yet high levels of social stigma inhibit testing among Nigerian youths and young men who have sex with (MSM). <h3>Objective</h3> To report pilot data from iCARE (Intensive Combination Approach to Roll Back Epidemic in Adolescents), a combination intervention using media peer navigation promote linkage care high-risk (hereinafter referred as<i>young men</i>), including predominantly MSM. <h3>Design, Setting,...